Our
News
Check back on a regualr basis
for futher updates.
First patient dosed for the first week in NG11-2 Phase Ib clinical trial
A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in Patients with Head & Neck Cancer
First patient enrolled in NG11-2 Phase Ib clinical trial
A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in Patients with Head & Neck Cancer.
VasoDynamics Receives Global Health & Pharma Biotechnology 2023 Award
VasoDynamics Receives Global Health & Pharma Biotechnology 2023 Award VasoDynamics receives Global Heath & Pharma Biotechnology Award 2023 as Most Patient-Centric Cancer Care Solutions Provider -
VasoDynamics Receives UK MHRA-REC Approval On NG11-2 Phase Ib Clinical Trial
VasoDynamics Receives UK MHRA-REC Approval On NG11-2 Phase Ib Clinical Trial A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral
VasoDynamics files UK patent for Radiotherapy-Induced Oral Mucositis (RIOM) Clinical Trial Methodology
VasoDynamics files UK patent for Radiotherapy-Induced Oral Mucositis (RIOM) Clinical Trial Methodology Establishes Intellectual Property protection for proprietary RIOM clinical trial design 22nd December 2022 -
VasoDynamics submits UK Clinical Trial Application for NG11-2
VasoDynamics submits UK Clinical Trial Application for NG11-2 A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in
